Dougherty & Co reissued their buy rating on shares of HemaCare (OTCMKTS:HEMA) in a research note released on Wednesday.
Shares of HEMA stock opened at $10.50 on Wednesday.
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.
Further Reading: How does a reverse stock split work?
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.